The company manufactures and trades pharmaceutical ingredients and healthcare products, having recently pivoted from its legacy business as Indsoya Limited to an integrated healthcare solutions provider.
The company operates in a highly fragmented and regulated commodity trading and manufacturing space with no discernible cost advantage or brand power. Low returns on capital and a recent total shift in business focus suggest the absence of any durable competitive advantage.
Management recently raised 50 million INR via a rights issue, but immediately diverted 30 million INR (60% of proceeds) to a 10-year lease with a related party, which was a deviation from the original stated objects of the issue.
The business collapsed as the capital raised from minority shareholders was systematically drained through related-party transactions, starting with the 60% diversion of rights issue proceeds into a long-term lease with insiders. Without a competitive advantage or pricing power, the core commodity trading operations failed to generate sufficient cash to cover overhead, while the lack of internal audit controls and frequent leadership turnover masked a deteriorating balance sheet. Eventually, the massive buildup in trade receivables proved uncollectible, revealing that the reported earnings were merely accounting fictions while the actual cash had been funneled to entities controlled by management.
RichFakir rates Apollo Ingredients Ltd's business quality as poor — 34/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Apollo Ingredients Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Apollo Ingredients Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Apollo Ingredients Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →